6 ms·
The article says that RNA encapsulation is the big bottleneck. This is a touchy microfluidic process. That needs to be accelerated. While few companies make tho
by Animats 6y ago
The article says that RNA encapsulation is the big bottleneck. This is a touchy microfluidic process. That needs to be accelerated. While few companies make those parts, more could. They're made by a process similar to that used in a wafer fab. A low-rez wafer fab, like the ones used to make MEMS gyros and such.
Part of the problem may be that wafer fab people and drug production people don't talk to each other much. Someone should get them talking.
Might come to nothing. Might lead to "oh, we can make that easily".
- Accujack 6y agoA chip isn't a complete device. What about the rest of the machinery? The software? Construction of the devices, calibration, testing and commissioning? There are probably less than 10 people worldwide capable of determining if machines like this (that probably only exist within the vaccine manufacturers) are set up correctly and working right. I suspect if you track down what's needed, you'll find that all the manufacturing capability for making more of those machines is already in use by the vaccine makers. Bespoke microfluidics devices aren't common or easy to make, although some components are.
- silexia 6y agoThe argument in the article for why the vaccine could not be produced is that there are new technical innovations that can't be done by other companies. I believe this to be a straw man argument. Each new human innovation is based on a massive mountain of previous human innovation. Many, many companies are on the edge of this innovation and allowing them to use the innovations of other companies without fear of patents litigation would allow them to make that last step now. Patents are one of the most insidious harms we have in our society today. Patent defenders claim that patents protect innovators. The truth is actually the exact opposite: patents are a monopoly legal tactic most often used so that the patent obtainer does not have to innovate further or execute. Patents kill all further innovation in the area they are in. A great example of this is that hundreds of companies used to manufacture aircraft. Boeing and Airbus bought up all the companies that own patents, and now it's nearly impossible to start a new aircraft manufacturing business due to Boeing's monopoly on the patents. Aircraft have changed very little ever since. We need to eliminate the patent system and allow free trade to actually work.
- visarga 6y agoI agree patents are harmful, especially in this situation, but the reason there are so few aircraft companies is because the tech matured and the standards of safety raised by a lot.
- Accujack 6y ago>Each new human innovation is based on a massive mountain of previous human innovation. That's a general rule of thumb, but it's not a law. There are innovations that are non sequels of previous developments. Sometimes inventors think differently than anyone else. The idea that multiple companies were "almost" on the edge of mRNA vaccines is pretty much proven false by the place the two existing companies got the tech - from the pair of people who developed it, one for each company.
- jackcviers3 6y agoIf you document the design and process, somebody else can copy it.
- selectodude 6y agoA lot of this stuff is pretty bespoke. I’m sure it’s not hard to get your hands on (especially now) but by the time it’s ready, nobody will need it.
- skybrian 6y agoIt seems like there are going to be a lot of mRNA vaccines?
- selectodude 6y agoI certainly hope so. I imagine if Moderna wanted more machines, they're en route. They also won't be ready until 2022.
- Robotbeat 6y agounfortunately we ARE going to need it because at current rates, billions of people won't be vaccinated until 2022 or 2023: https://www.npr.org/sections/coronavirus-live-updates/2021/01/22/959627186/until-everyone-is-safe-no-one-is-safe-africa-awaits-the-covid-19-vaccine https://www.npr.org/sections/coronavirus-live-updates/2021/0... That's billions of people who will be incubating more mutated variants of COVID-19. And secondly, we'll need that equipment for COVID-19 variant booster shots. (And will come in handy for vaccinating with a universal flu vaccine, even HIV, etc.)
- refurb 6y agoNo. Someone else can't copy it. With new technology like this there is often a ton of fairy dust involved - knowledge gained by the people who developed it that even they aren't aware is critical to the process. I was involved in a relatively simple tech transfer of a pharmaceutical agent to a plant in China. We pulled it back to the US because every single batch failed. And it wasn't due to shoddy workmanship since we had US people on the ground directing everything.
- danvoell 6y ago"Part of the problem may be that wafer fab people and drug production people don't talk to each other much." - Another part of the problem is probably regulation. Water companies don't want to inadvertently bypass FDA regulation. Drug production folks don't want to teach water folks the FDA approval process, such that, they could become future competition.... Sheer speculation.
- vmception 6y agowhether they actively think about it or not, the disincentives are there and should be addressed
- Robotbeat 6y agoAnd a pandemic is a good time to put an FDA bureaucrat, an army logistics expert, a manufacturing expert, and a drug expert along with unlimited funding on a private jet that can fly out to all these companies with a federal order signed by the president with authorization from Congress compelling companies to cooperate and with authority to cut through all red tape and IP law (with appropriate manpower to work with companies to ensure everything is done safely). Find every bottleneck and immediately fly out to the next company.
- hoseja 6y agoDo you really think government has power over companies anymore, and not the other way around? Future pharma profits must be protected at all costs. This "nationalizing essential drugs" business could set a dangerous precedent after all.
- foofoo55 6y agoHere's a commercial RNA encapsulation system: https://www.precisionnanosystems.com/platform-technologies/product-comparison/gmp-system https://www.precisionnanosystems.com/platform-technologies/p...
- Animats 6y agoRight. That's the next stage up, pumps, plumbing, and instrumentation. The "cartridge" mentioned is the hard part. Here's a company which makes the "chips" which go in such cartridges.[1] And here are some chips.[2] Making those involves etching tiny patterns in glass, lining the channels with various coatings, and assembling the layers of glass into devices. All this has to be done in a very clean environment. Note the similarity to the processes in a wafer fab. The point here is that the semiconductor industry has many processes and tools which might be helpful if there's a need to manufacture microfluidic components in quantity. [1] https://www.dolomite-microfluidics.com/ https://www.dolomite-microfluidics.com/ [2] https://www.dolomite-microfluidics.com/product-category/microfluidic-components/microfluidic-chips/ https://www.dolomite-microfluidics.com/product-category/micr...
- rossdavidh 6y agoIf we had a long-term bottleneck here, there might be some possibility here, but then again if there were a long-term bottleneck we could just build more capacity. However similar they are, I doubt you can just turn this on in a month or two without serious potential issues, and given how many people the vaccine is going into you have way more potential downside than potential upside. Which is really the issue with all potential fixes: either they are unknown and thus unacceptably risky for something we will use on hundreds of millions (or billions) of people, or if we take the time to get to acceptable risk it will be too late to really help with this issue.
- Robotbeat 6y agoWe've had since February. That is checks watch an entire year now. Not just one or two months. And it's something we could've been doing in parallel with approval.
- rossdavidh 6y agoSure, and it would have been awesome if we had, BUT...this is, as I understand it, the very first case of an mRNA vaccine getting mass produced. There were literally scores of different vaccines, of a variety of technologies, being researched for this. I bet lots of vaccines were "ready" in February, the many of which did not pan out. If you had to bet on which one(s) to prep extra production for, mRNA is probably not (in February) what would have been picked.
- Robotbeat 6y agoI would have picked it! In fact, when you’re faced with a civilization-wide once-in-a-century pandemic, you pick ALL of them. You invest billions of each. The top dozen get tens of billions. Each month, evaluate most promising approaches, and add more. I knew in February or March that the mRNA vaccines were extremely promising. NIH experts knew earlier than I did. The mRNA approaches had a head start because they had been studying MERS and SARS-1 before COVID-19. They hit the ground running once the sequence of the virus was released. It was known nearly immediately that they were promising approaches. That there were hyper-conservative uberskeptics that didn’t think so (and hadn’t actually been following such approaches in detail) and snootily spoke in the press about that doesn’t change what the real experts who were keeping abreast to the latest developments thought.
- xjlin0 6y agoThere are many fancy kitchen machines out there. But even you buy me one, it's impossible for me to cook great dishes overnight. Same things goes to wafer fab, buying me the most advanced limask alignerhography machine can not make me to be able to produce great 5nm chips in a few years. Also the instrumental parameters from manufacturer A probably cannot be applied directly to the instrument from manufacturer B. It is an entire process/system that can not be reproduced overnight. It takes time.
- baybal2 6y agoI'm thinking if lipid nanoparticles can be made by strong shear forces, or be made to just emulsify with the RNA.